Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August
You may also be interested in...
Japanese Government Looks To Increase Funding For Cancer Research
TOKYO - Aggregate fiscal 2009 budget requests for cancer research, treatment and other administrative measures of the Japanese government would grow 10.8 percent from fiscal 2008 to ¥60.5 billion ($672 million), according to the budget requests of the Ministry of Health, Labor and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; and the Ministry of Economy, Trade and Industry
Japanese Government Looks To Increase Funding For Cancer Research
TOKYO - Aggregate fiscal 2009 budget requests for cancer research, treatment and other administrative measures of the Japanese government would grow 10.8 percent from fiscal 2008 to ¥60.5 billion ($672 million), according to the budget requests of the Ministry of Health, Labor and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; and the Ministry of Economy, Trade and Industry
MHLW 2009 Budget Requests ¥1.4 Billion To Strengthen PDMA Safety Measures
The Ministry of Health, Labor and Welfare released Aug. 26 a budget request for fiscal year 2009 of ¥22.85 trillion, an ¥829.2 billion and 3.8 percent increase compared to FY 2008's initial budget. The budget allocates ¥48.2 billion to stock up on flu drugs such as Tamiflu (oseltamivir)and Relenza (zanamavir) and pre-pandemic vaccines, and to develop pandemic vaccines. ¥33.2 billion is designated to develop new drugs in the areas of cancer, mental disorder, intractable and rare diseases and regenerative medicine. To boost safety measures in drugs and medical devices, ¥1.4 billion is allocated to the Pharmaceutical and Medical Device Agency to increase staff, and ¥900 million to the PDMA in establishing a consulting system to promote Japan-U.S.-Europe joint clinical trials and concurrent reviews for medical device. (Click here for more - Japanese language